Motus GI Announces Presentation Of Results From Independent Study Of Pure-Vu System In IBP Patients At 2021 ACG Annual Scientific Meeting
Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency
How Bad Are Motus GI Hldgs’s Earnings? | Return On Capital Employed
Motus GI Hldgs (NASDAQ:MOTS) brought in sales totaling $100.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 3.33%, resulting in a loss of $4.59 million.
Motus GI Hldgs Q2 EPS $(0.10) Beats $(0.13) Estimate, Sales $100.00K Beat $60.00K Estimate
Motus GI Hldgs (NASDAQ:MOTS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 33.33 percent increase over losses of $(0.15) per share from
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Top 20 Searched Tickers In Benzinga Pro For Morning Of Friday, Apr. 30, 2021
NIO (NIO)
Amazon (AMZN)
Microvision (MVIS)
Tesla (TSLA)
Vaxart (VXRT)
Galera Therapeutics (GRTX)
ShiftPixy (PIXY)
Apple (AAPL)
Twitter (TWTR)
Ocugen (OCGN)
Motus GI (MOTS)
Facebook (FB)
SPDR S&P 500
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Artelo Biosciences (NASDAQ:ARTL) stock rose 5.26% to $1.2 during Tuesday's after-market session. This security traded at a volume of 43.6K shares come close, making up 0.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $27.7 million.